Post New Job

RSV jab reduced infant hospital admissions by 83%, study reports

The long acting monoclonal antibody nirsevimab (marketed as Beyfortus) reduced respiratory syncytial virus associated hospital admissions in infants by 83%, a study has found.1

More than 8000 infants aged 12 months or under in France, Germany, and the UK took part in the study and were randomly assigned to either receive nirsevimab (4037 infants) or standard care (no intervention, 4021 infants) before or during their first RSV season (September and October 2022).

The study, funded by the drug companies Sanofi and AstraZeneca, reported that 11 infants (0.3%) in the nirsevimab group and 60 (1.5%) in the standard group were …

Source link

  • Share this post

Leave a Comment

 
Required 'Candidate' login to applying this job. Click here to logout And try again
 
 

Answers

 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.